Hepatitis C Virus Infection Is Blocked by HMGB1 Released from Virus-Infected Cells

Jong Ha Jung,1 Ji Hoon Park,1 Min Hyeok Jee,1 Sun Ju Keum,1 Min-Sun Cho,2 Seung Kew Yoon,3 and Sung Key Jang1,4,5*

PBC, Department of Life Science,1 Division of Integrative Biosciences and Biotechnology, WCU Program,4 and Biotechnology Research Center,5 Pohang University of Science and Technology, Pohang, Kyungbuk, Republic of Korea; Department of Pathology, Ewha Womans University School of Medicine, Seoul, Republic of Korea2; and Department of Internal Medicine & WHO Collaborating Center of Viral Hepatitis, Catholic University, Seoul, Republic of Korea3

Received 5 April 2011/Accepted 25 June 2011

High-mobility group box 1 (HMGB1), an abundant nuclear protein that triggers host immune responses, is an endogenous danger signal involved in the pathogenesis of various infectious agents. However, its role in hepatitis C virus (HCV) infection is not known. Here, we show that HMGB1 protein is translocated from the nucleus to cytoplasm and subsequently is released into the extracellular milieu by HCV infection. Secreted HMGB1 triggers antiviral responses and blocks HCV infection, a mechanism that may limit HCV propagation in HCV patients. Secreted HMGB1 also may have a role in liver cirrhosis, which is a common comorbidity in HCV patients. Further investigations into the roles of HMGB1 in the diseases caused by HCV infection will shed light on and potentially help prevent these serious and prevalent HCV-related diseases.

Hepatitis C virus (HCV) is one of the major causative agents of hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) (17, 30). More than 170 million people are estimated to suffer from HCV infection worldwide (17). Chronic and persistent infection is a characteristic feature of HCV pathogenesis (30). During chronic infection, the production of virus particles is limited, and a restricted number of liver cells are infected. As a result, the viral dose in patients’ blood generally is lower than that of other hepatitis-causing viruses, such as hepatitis B virus (HBV) (4). Moreover, a large portion of hepatocytes often remains uninfected by the virus even after long-term infection (28). These phenomena indicate the existence of balance between the HCV infection process and host mechanisms that protect against HCV infection. We speculate that innate and adaptive immunities contribute to the balance between infection and protection.

High-mobility group box 1 (HMGB1) protein is a highly conserved nuclear protein that participates in DNA organization and the regulation of transcription. In addition to its nuclear function, HMGB1 plays an important role as a cytokine, mediating the responses to infection, injury, and inflammation (1, 2, 29, 42). HMGB1 is released passively from necrotic cells and is actively secreted from activated immune cells, such as macrophages, natural killer cells, and mature dendritic cells (2). The functionality of actively secreted HMGB1 is known to be modulated by posttranslational modifications, such as oxidation (2, 36). Extracellular HMGB1 can function by itself and/or in association with other molecules, including CpG DNA, lipopolysaccharide (LPS), and interleukin-1 (IL-1) (5). HMGB1 induces a variety of cellular responses that contribute to innate immunity, tissue repair, and cell migration through interactions with various receptors that activate multiple signal transduction responses. The Toll-like receptors (e.g., TLR2, TLR4, and TLR9) and the receptor for advanced glycation end products (RAGE) are known receptors for the cytokine functions of HMGB1 (2). TLR4, the major component of the LPS recognition receptor complex, engages in downstream signaling through MyD88 and the Toll-like adapter protein TRIF to produce proinflammatory cytokines and type I interferons (IFNs), which potentially participate in blocking virus infections (34).

No role of HMGB1 in HCV infection has been demonstrated yet. However, HMGB1 is known to be an indicator of human liver injury (19), and HMGB1 levels in the sera of patients with chronic hepatitis and cirrhosis are significantly elevated (8). The source of this elevated serum HMGB1 and the molecular mechanism responsible for the secretion of HMGB1 from cells are not known. One possible mechanism underlying elevated HMGB1 secretion is increased reactive oxygen species (ROS) in HCV-infected cells. Two HCV-encoded proteins, core and NS5A, induce oxidative stress in infected cells (15, 25–27), and it has been reported that ROS induces nuclear-to-cytoplasmic translocation and the subsequent secretion of HMGB1 from cells (36). However, the localization of HMGB1 in HCV-infected cells and the effect of HMGB1 on HCV infectivity remain to be elucidated.

Here, we investigated the localization and secretion of HMGB1 upon HCV infection. We found that some HMGB1 protein was translocated from the nucleus to the cytoplasm and secreted into the medium before virus production was observed. This suggests that HCV-infected cells sense the HCV infection and propagate a warning signal to uninfected cells. We tested the potential role of secreted HMGB1 in HCV infection using an antibody against HMGB1 and purified...
cell. The treatment of HCV culture medium with the anti-HMGB1 antibody increased the infectivity of HCV. Conversely, the pretreatment of cells with purified HMGB1 protein reduced the infectivity of HCV, indicating that HMGB1 secreted from infected cells blocked the infection of neighboring cells by HCV. Our investigation of the molecular basis of this protection further revealed that TLR4, a potential HMGB1 receptor, plays an important role in the antiviral effect via the activation of interferon signaling.

**MATERIALS AND METHODS**

**Cell culture and HCV production.** The human hepatoma cell line Huh7.5.1 was kindly provided by Francis V. Chisari (Scripps Research Institute). Huh7.5.1 and HEK293FT (human kidney carcinoma) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (FBS; HyClone), penicillin, and streptomycin. The in vitro synthesis of HCV RNA (derived from JFH1 and JFH1s-RLuc vectors) and electroporation were performed as described previously (22). Infectious HCV in cell culture (HCVcc) was produced by the transfection of Huh7.5.1 cells with in vitro-transcribed HCV RNA. The virus titer was determined as described elsewhere (11) and stored at −80°C.

**Reagents.** The antibodies against HMGB1, TLR4, and isotype control IgG were purchased from Abcam. The antibody against HCV core for immunocytochemistry was obtained from Affinity Bioreagents. The antibodies to PARP [poly(ADP-ribose) polymerase], β-actin, and GAPDH (glyceraldehyde 3-phosphate dehydrogenase) were obtained from Santa Cruz Biotechnology, Sigma, and AbD Serotec, respectively. The secondary antibodies for immunostaining were purchased from Invitrogen and Jackson ImmunoResearch. The antibody against HCV core for Western blotting was a gift from Raif Bartenschlager (University of Heidelberg). LPS and Hoechst 33258 were obtained from Sigma.

**Patient tissue.** Informed consent to use tissue specimens for research purposes was obtained from all patients, and the utilization of specimens for this research was approved by the Institutional Review Boards of the College of Medicine, Ewha Womans University (case numbers S10-6410 and S09-2974), Yonsei University (case number T6), and Catholic University (case number 14266130).

**RT-PCR.** Total RNA was purified with TRI reagent, and cDNA was synthesized using reverse transcription reagents (Promega). Reverse transcription-PCR (RT-PCR) was performed using a LightCycler 480 SYBR green I master system (Roche). Primer sequences for reverse transcription, PCR, and real-time PCR were the following: IFNβ1, 5'-CAG CAA TTT TCA GTG TCA GGA GC-3' and 5'-TCA TCC TGT CCT TGT GGC AG-3'; interferon-stimulated gene 15 (ISG15), 5'-ACT CAT TCG TAC GAG AGG AG-3' and 5'-CAG CAT CTC CGT GAT GTC-3'; GAPDH, 5'-TGC ACC ACC TAC GTG TTA G-3' and 5'-GAG GCA GGA ATG ATG TTC TTT-3'; and β-actin, 5'-CTG GAA CGG TGA AGG TGACA-3' and 5'-AAG CGA CCT CTT GGA ATG A-3'.

**Transfection of DNA and siRNA.** Cells seeded on 12-well plates (4 × 10⁵ cells/well) were transfected with siRNAs (20 nM final concentration) and DNAs (1 µg/well) using Oligofectamine (Invitrogen) and Fugene HD (Roche), respectively, according to the manufacturer’s instructions. The small interfering RNA (siRNA) targeting human TLR4 mRNA (5'-CUG CAU AUA GUA UGG UAG A-3') and a control siRNA were purchased from Bioneer Inc. (South Korea).

**Luciferase assay.** Luciferase assays were performed using a luciferase assay kit (Promega) according to the manufacturer’s instructions. Luciferase activity in cells was normalized to protein concentrations determined by Bradford assays.

**Statistical analysis.** Results are expressed as means ± standard deviations. Comparisons between two groups were performed using Student’s t test. Differences with P values <0.05 were considered significant.

**RESULTS**

HCV infection promotes nuclear-to-cytoplasmic translocation of HMGB1 in virus-infected cells. The subcellular localization of HMGB1 changes depending on environmental conditions. For instance, oxidative stress induces HMGB1 translocation from the nucleus to the cytoplasm (37, 38). Because HCV infection induces ROS production (9, 40), we assessed HMGB1 dynamics during HCV infection using an immunocytochemical method with confocal immunofluorescence microscopy detection. Huh7.5.1 cells were mock infected or infected with HCV (JFH1; multiplicity of infection of 1), grown on glass coverslips, fixed with paraformaldehyde, and processed for indirect immunofluorescence with anti-core and anti-HMGB1 antibodies. One day postinfection (1 dpi), HCV core proteins were observed mainly around lipid droplets (Fig. 1A). Interestingly, a portion of HMGB1 protein was translocated from the nucleus to the cytoplasm in HCV-infected cells within 1 dpi, when the viral protein core could first be detected by Western blotting, although a majority of the protein remained in the nucleus (Fig. 1A and B). Consistently with this, the amount of HMGB1 in the cytoplasm increased more than 3-fold at 1 and 2 dpi, as monitored by the fractionation of cell extracts and Western blotting (Fig. 1B). Moreover, the secretion of HMGB1 into the medium after HCV infection was detected at 1 and 2 dpi by Western blotting, even though no cytopathic effects were observed at these time points (Fig. 1C).
FIG. 1. Translocation of HMGB1 in HCV-infected cells. (A) Huh7.5.1 cells infected with JFH or mock infected were analyzed immunocytochemically 1 day (1d) or 2 days (2d) after infection using an anti-HCV core (green) or anti-HMGB1 (red) antibody. Representative fluorescence micrographic images (HMGB1 and Core) and merged images (Merged) are shown. Combined merged and differential interference contrast microscopic (DIC) images (Merged + DIC) also are shown. Scale bar, 5 μm. (B) Cell extracts from Huh7.5.1 cells, mock infected or HCV infected for 1 or 2 days, were divided into cytosolic (Cyt) and nuclear (Nu) fractions. The fractionation efficiency was confirmed by Western blotting for PARP and GAPDH, which are representative nuclear and cytoplasmic proteins, respectively. The infection of HCV was confirmed by the production of HCV core protein (Core). The intensities of nuclear and cytoplasmic HMGB1 protein were analyzed by Western blotting (HMGB1). The intensities of HMGB1 protein bands were quantified densitometrically using ImageJ software. Band intensities of nuclear and cytoplasmic HMGB1 were normalized to those of GAPDH and PARP, respectively. Band intensity values relative to those in mock-infected cells are depicted in the bottom panel. The mean values and standard deviations are depicted as numbers and bars, respectively (*, P < 0.05 versus the mock-infected group). (C) The amount of HMGB1 protein secreted by HCV-infected and uninfected cells was analyzed by Western blotting with an anti-HMGB1 antibody. (D) The viability of Huh7.5.1 cells before and 1 and 2 days after HCV infection was determined by measuring the release of adenylate kinase (AK) from damaged cells into the culture medium using the ToxiLight BioAssay kit (Cambrex) according to the manufacturer's instructions. The means and standard deviations are depicted as numbers and bars, respectively.
and D). These results indicate that HCV infection triggers the translocation and secretion of HMGB1 proteins in virus-infected cells.

**Cytoplasmic HMGB1 is observed in HCV-infected cells of HCV patients.** To confirm the physiological relevance of the translocation of HMGB1 in HCV-infected cells, we monitored the subcellular localization of HMGB1 in the livers of HCV patients.

HMGB1 proteins were detected mainly in the nuclei of normal liver cells (Fig. 2A, first row) and uninfected liver cells (defined by the absence of HCV core protein) of an HCV patient (Fig. 2A, asterisked cells in the second row), whereas a large portion of HMGB1 proteins was observed in the cytoplasm of HCV-infected liver cells from the same patient (Fig. 2A, second row). A similar redistribution of HMGB1 protein was also observed in liver cancer tissues from patients infected with HCV (Fig. 2A, third and fourth rows). The redistribution of HMGB1 protein was confirmed by quantitative analyses of fluorescence intensities corresponding to HMGB1, HCV core, and Hoechst (Fig. 2B and C). A more than 10-fold increase of cytoplasmic HMGB1 was observed in the HCV-infected cells (Fig. 2C). Patient clinical data are summarized in Table 1. As noted above, elevated levels of HMGB1 have been observed in
the sera of patients with liver diseases, such as chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (8). Taken together with this previous report, these data suggest that secreted HMGB1 is involved in the pathogenesis of HCV.

**Extracellular HMGB1 blocks HCV infection.** Because various cytokine functions of HMGB1 have been reported, we next investigated the effect of secreted HMGB1 on HCV infection. First, the effect of an anti-HMGB1 antibody on HCV infection was monitored by adding the antibody to culture medium after HCV (JFH/5αRluc) infection (22). This virus contains the *Renilla* luciferase gene inserted into the NS5A region and allows the quantitative measurement of HCV infectivity (22). We measured luciferase activity in Huh7.5.1 cells at 3 dpi, a time that corresponds to the first and second rounds of HCV infection. Under these conditions, this experiment monitors the autocrine and/or paracrine effects of HMGB1. We found that the HMGB1 antibody, but not the control antibody, augmented HCV infection up to 176% in a dose-dependent man-

**TABLE 1. Clinical background of HCV patients**

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Age (yr)</th>
<th>Gender</th>
<th>Tumor diagnosis</th>
<th>Tumor size</th>
<th>Tumor grade</th>
<th>% Necrosis</th>
<th>Etiology</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>14266130</td>
<td>53</td>
<td>F</td>
<td>Hepatocellular carcinoma</td>
<td>4 × 3</td>
<td>2−3</td>
<td>0</td>
<td>Anti-HCV negative</td>
<td>Within normal limits</td>
</tr>
<tr>
<td>S10-6410</td>
<td>63</td>
<td>F</td>
<td>Hepatocellular carcinoma</td>
<td>6.4 × 6.5</td>
<td>1−2</td>
<td>0</td>
<td>HCV (2a)</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>S09-2974</td>
<td>61</td>
<td>M</td>
<td>Hepatocellular carcinoma</td>
<td>4 × 3</td>
<td>2−3</td>
<td>0</td>
<td>HCV (2b)</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>T6</td>
<td>61</td>
<td>M</td>
<td>Hepatocellular carcinoma</td>
<td>6.4 × 6.5</td>
<td>1−2</td>
<td>0</td>
<td>HCV</td>
<td>Fibrosis</td>
</tr>
</tbody>
</table>

*a* F, female; M, male.
The anti-HCV activity of HMGB1 proteins secreted from HCV-infected cells at least partially block the rapid propagation of HCV infection.

**The anti-HCV activity of HMGB1 is mediated by TLR4.** To understand the molecular basis of the anti-HCV effect of HMGB1, we sought to identify the cellular receptor of HMGB1 that mediates HMGB1 signaling. We speculated that TLR4 was the most likely receptor candidate, since it not only triggers proinflammatory responses through NF-κB activation like other potential receptors (RAGE, TLR2, and TLR9) but also mediates antiviral responses through the activation of IFN response factor 3 (IRF-3) (2). To test this supposition, we knocked down TLR4 with siRNA and examined HCV infectivity. siRNA-mediated TLR4 knockdown (Fig. 4B) augmented HCV infection by about 40% (Fig. 4A). Conversely, the overexpression of TLR4 (Fig. 4D) reduced HCV infection by about 25% compared to that of mock-transfected cells (Fig. 4C). To further confirm the TLR4-mediated HMGB1 signaling, we investigated whether the knockdown of TLR4 renders HCV replication resistant to exogenous HMGB1 treatment. HCV production in the presence of exogenous HMGB1 was increased by 80% in TLR4 knockdown cells (Fig. 4E), and the inhibitory effect of the exogenous HMGB1 on HCV production in TLR4 knockdown cells was reduced significantly (from 44 to 28%) compared to that of control siRNA-transfected cells (Fig. 4E). The remaining inhibitory effect of HMGB1 in the siRNA-treated cells likely is attributable to the residual TLR4 proteins on the siRNA-transfected cells and/or to other putative HMGB1 receptors, such as TLR2, TLR9, and RAGE, that might exist on the hepatocyte cells. These data indicate that TLR4 is responsible, at least in part, for mediating the anti-HCV activity of HMGB1.

**HMGB1 triggers an interferon response.** We further analyzed the molecular basis of the antiviral activity of HMGB1 by testing the induction of the antiviral protein beta interferon (IFN-β), which blocks HCV proliferation (13), and IFN-stimulated gene 15 (ISG15), which is a good marker for the induction of interferon-responsive genes (33). Both IFN-β and ISG15 were greatly induced in Hu7.5.1 cells, the same cells used in HCV infection studies, by treatment with wild-type HMGB1 for 48 h (Fig. 5A). LPS, a positive control that triggers TLR4 signaling, also induced the expression of interferon-related genes (Fig. 5A). In contrast, treatment with mutant HMGB1-C106S produced a very limited induction of IFN-β and ISG15 (Fig. 5A). No reagents induced the expression of the negative control, GAPDH (Fig. 5A). To further validate the role of TLR4 in HMGB1-mediated signaling, we investigated the induction levels of IFN-β and ISG15 in TLR4 knockdown cells by treating wild-type HMGB1 for 48 h. As shown in Fig. 5B, the induction of IFN-β and ISG15 with wild-type HMGB1 treatment in the siRNA against TLR4-transfected cells was reduced by 63 and 39%, respectively, compared to that of the control siRNA-transfected cells. These data strongly suggest that secreted HMGB1 exerts anti-HCV activity by triggering an interferon response in HCV-infected cells and neighboring cells.

**DISCUSSION**

Here, we provide the first demonstration that HCV infection triggers the translocation of a portion of HMGB1 protein from

---

**FIG. 3. Effects of secreted HMGB1 protein on HCV infection.** (A) Hu7.5.1 cells were inoculated with JFH/5aRluc virus for 4 h and then cultivated further in fresh medium containing different amounts of anti-HMGB1 or control IgG antibodies for 3 days. HCV-infected cells were lysed with passive lysis buffer, and luciferase assays were performed to monitor the proliferation of HCV. Luciferase activity in lysates (RLU values) was normalized to protein levels measured by Bradford assays. The mean values and standard deviations are depicted as numbers and bars, respectively (*, P < 0.05; **, P < 0.01 versus the mock-infected group). (B) Hu7.5.1 cells were treated with purified wild-type HMGB1 (30 or 300 ng/ml) or mutant HMGB1-C106S (30 or 300 ng/ml) proteins for 18 h and then infected with JFH/5aRluc virus for 3 days. HCV-infected cells were lysed with passive lysis buffer, and luciferase assays were performed to monitor the proliferation of HCV. RLU values were normalized to protein levels measured by Bradford assays. The mean values and standard deviations are depicted as numbers and bars, respectively (*, P < 0.05 versus the mock-infected group).
the nucleus to the cytoplasm and induces HMGB1 secretion into the extracellular milieu (Fig. 1 and 2). The release of HMGB1 protein from cells infected by various viruses has been reported previously. For instance, both RNA virus (West Nile virus, Dengue virus, and HIV-1 [3, 7, 10, 20]) and DNA virus (herpes simplex virus type 2 [6]) infections have been shown to result in the secretion of HMGB1 through apoptosis and/or necrosis. It has been further suggested that HMGB1...
protein secreted in response to viral infections contributes to the pathogenesis of these infections (39). The elevation of HMGB1 levels in the plasma of HCV patients with chronic hepatitis, liver cirrhosis, and HCC (8) likely is attributable to both the active secretion of HMGB1 and cytopathic effects of HCV infection, even though we showed that the secretion of HMGB1 can occur without killing the HCV-infected cells from an in vitro HCV culture system (Fig. 1D).

In the current study, we focused on the function of secreted HMGB1 protein. Using an anti-HMGB1 antibody and purified HMGB1 protein, we showed that secreted HMGB1 partially blocks HCV infection (Fig. 3). This is the first report demonstrating an anti-HCV effect of HMGB1. By monitoring the effects of TLR4 knockdown and overexpression on HCV infection, we also showed that the anti-HCV effect of HMGB1 is mediated, at least in part, by TLR4 (Fig. 4). Moreover, we showed that HMGB1 induces the expression of interferon-related genes in the hepatocellular carcinoma cell line (Huh7.5.1) used in HCV infection studies (Fig. 5). These data lead us to conclude that HCV infection induces the secretion of HMGB1 protein into the extracellular milieu, and secreted HMGB1 triggers the production of antiviral proteins through TLR4-mediated interferon responses. We speculate that the anti-HCV effect of HMGB1 at least partly contributes to limiting the propagation of HCV in HCV patients. Moreover, secreted HMGB1 is likely to trigger inflammatory responses (16) by activating neighboring immune cells, such as Kupffer cells and hepatic dendritic cells, to release more proinflammatory cytokines. Therefore, HMGB1 by itself or in combination with other proinflammatory cytokines also may contribute to the chronic inflammation of liver cells (hepatitis) in HCV patients. Because TLR4 enhances the signaling of TGF-β, which is the cytokine best known to trigger liver cirrhosis and promote hepatic fibrosis in quiescent hepatic stellate cells (31), secreted HMGB1 also may be associated with liver cirrhosis, another pathological symptom caused by HCV infection. The involvement of TLR4 in liver cirrhosis also was strongly supported by a recent study indicating that a single-nucleotide polymorphism of TLR4 is the key factor in significantly reducing the risk of developing cirrhosis in patients with chronic HCV infection (18). These observations support the view that secreted HMGB1 functions as a double-edged sword: it pro-

---

**FIG. 5.** Induction of interferon-related genes by HMGB1 protein. (A) The mRNA levels of the interferon-related genes, IFN-β and ISG15, and the control gene, GAPDH, in Huh7.5.1 cells were monitored by quantitative RT-PCR after treatment with HMGB1 (300 ng/ml), HMGB1-C106S (300 ng/ml), or LPS (2 μg/ml) for the indicated times. The changes in mRNA concentration, normalized to the level of control mRNA (β-actin) 3 h after treatment, are depicted. The values presented in the graphs are means and standard deviations. (B) Huh7.5.1 cells were transfected with an siRNA against TLR4 or a control siRNA using Oligofectamine. After 1 day of cultivation, siRNA-transfected cells were treated with purified wild-type HMGB1 (300 ng/ml) or mutant HMGB1-C106S (300 ng/ml) for 48 h. The mRNA levels of IFN-β, ISG15, and β-actin were measured as described for panel A (*, P < 0.05 versus the control siRNA-transfected group).
tects hepatocytes from infection while at the same time contributing to triggering and maintaining a pathological status (e.g., in hepatitis and liver cirrhosis). Confirming the roles of HMGB1 in HCV pathology and the physiological activities of HMGB1 during HCV infection will require further investigation using appropriate animal model systems.

The molecular basis of the translocation of HMGB1 during HCV infection is not fully understood. However, the most likely mechanism involves ROS generated in HCV-infected cells. HCV proteins are known to cause endoplasmic reticulum (ER) stress, which results in the release of calcium from the ER. The released calcium, in turn, reduces mitochondrial membrane potential and increases ROS production (27). For example, HCV core and NS5A proteins induce oxidative stress in HCV-infected cells (15, 25, 26). In addition, it is known that HMGB1 proteins are translocated from the nucleus to the cytoplasm or even secreted into the extracellular milieu under conditions in which intracellular ROS levels are elevated (36). We confirmed that ROS was elevated in HCV-infected cells (data not shown) and demonstrated that HMGB1 was secreted from cells treated with H2O2, which increased intracellular ROS levels (data not shown). These observations suggest that the elevated levels of ROS in HCV-infected cells contribute, at least in part, to the translocation of HMGB1.

Although this study did not focus on the role of cytoplasmic HMGB1, it is worth emphasizing the potential significance of the translocation of HMGB1 from the nucleus to the cytoplasm (Fig. 1A and B and 2). One possibility is that cytoplasmic HMGB1 is involved in the induction of autophagy in HCV-infected cells. Autophagy is known to play an important role in host immunity against virus infections (23). On the other hand, autophagy is known to be required for HCV replication (12), and the knockdown of proteins involved in autophagy enhances the innate immune response in HCV-infected hepatocytes (21, 32). A relationship between autophagy and HMGB1 enhances the innate immune response in HCV-infected hepatoctyes (21, 32). A mechanism in which intracellular ROS levels are elevated (36).

HMGB1, it is worth emphasizing the potential significance of the translocation of HMGB1 during sterile inflammation and infection. Annu. Rev. Immunol. 29:139–162.

REFERENCES

33. Skagg, B., and Z. J. Chen. 2010. Emerging role of ISG15 in antiviral immu-